Tocilizumab biosimilar (Gedeon Richter/Mochida Pharmaceutical)

托珠单抗生物类似药 (Gedeon Richter/Mochida Pharmaceutical)

Report date: 2026/05/25 20:02:40

Base Information

Drug NameTocilizumab biosimilar (Gedeon Richter/Mochida Pharmaceutical)
Drug Alias NameLusiNEXTuyory
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 inhibitorsImmunosuppressants
TargetsInterleukin-6
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Cytokine Release SyndromeGiant Cell Arteritis +[5] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)Cytokine Release SyndromeGiant Cell Arteritis +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2026/05/19
Country/TerritoryAustraliaEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMycenax Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesGedeon RichterChemical Works of Gedeon Richter PlcMycenax Biotech Inc +[4] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Cytokine Release SyndromeGiant Cell Arteritis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AC07
Related LinksN/A